{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:43:39Z","timestamp":1790689419882,"version":"4.1.0"},"reference-count":55,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined as steatotic liver disease with at least one cardiometabolic risk factor, in the absence of harmful alcohol intake, and includes a spectrum of conditions. These range from isolated liver steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and MASH-related hepatocellular carcinoma. Patients with MASLD and type 2 diabetes are at increased risk of developing MASH and significant\/advanced fibrosis. The severity of fibrosis is a key determinant of long-term prognosis in MASLD. The most recent AASLD and EASL-EASD-EASO Guidelines on the Management of MASLD recommend a step-by-step approach to identify patients at higher risk of fibrotic progression. Recent epidemiological trends highlight the socioeconomic impact of MASLD and MASH, particularly in middle- and low-income countries. Given the high cost of new targeted therapies, implementing effective treatment strategies in low-resource settings is essential in managing MASLD and MASH patients. Pioglitazone is an oral antidiabetic agent of the thiazolidinedione class that targets peroxisome proliferator-activated receptors activated by fatty acids and derivatives or pharmacological agonists and involved in lipid metabolism, cell differentiation, and inflammation. Pioglitazone treatment is a potential cost-effective option, particularly for low-resource settings. This review examines recent epidemiological trends in MASLD and MASH, outlines the mechanisms of action of pioglitazone with an emphasis on its role in improving liver fibrosis, and summarizes clinical studies on fibrosis evaluation during pioglitazone treatment. The literature search focused on English-language studies from the past two years in the PubMed database.<\/jats:p>","DOI":"10.3390\/life15111682","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:38:22Z","timestamp":1761759502000},"page":"1682","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Improvement of Liver Fibrosis in Patients with MASLD Undergoing Pioglitazone Treatment: An Update"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9146-9968","authenticated-orcid":false,"given":"Cristina","family":"Stasi","sequence":"first","affiliation":[{"name":"Department of Life Science, Health and Health Professions, Link Campus University, 00165 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0458-3763","authenticated-orcid":false,"given":"Andrea","family":"Mega","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Bolzano Regional Hospital, 39100 Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"ref_1","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol., 81, 492\u2013542."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: An updated systematic review and meta-analysis","volume":"72","author":"Ang","year":"2023","journal-title":"Gut"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Stasi, C. (2025). Post-COVID-19 Pandemic Sequelae in Liver Diseases. Life, 15.","DOI":"10.3390\/life15030403"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Nour, T.Y., and Altinta\u015f, K.H. (2023). Effect of the COVID-19 pandemic on obesity and it is risk factors: A systematic review. BMC Public Health, 23.","DOI":"10.1186\/s12889-023-15833-2"},{"key":"ref_5","unstructured":"World Heart Federation (2025, May 16). World Heart Report 2025. Obesity & Cardiovascular Disease. Available online: https:\/\/world-heart-federation.org\/resource\/world-heart-report-2025\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100747","DOI":"10.1016\/j.gastha.2025.100747","article-title":"Validation of the American Association for the Study of Liver Disease\/European Association for the Study of the Liver Multistep Screening Strategies for Metabolic Dysfunction-associated Steatotic Liver disease","volume":"4","author":"Canivet","year":"2025","journal-title":"Gastro Hep Adv."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Vidal-Tr\u00e9can, T., Julla, J.B., El Khoury, T., Venteclef, N., Riveline, J.P., Paradis, V., Valla, D., Gautier, J.F., and Castera, L. (Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc., 2025). Effectiveness of Six International Guidelines Using Fibrosis-4 and FibroScan for Risk Stratification of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes, Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc., advance online publication.","DOI":"10.1016\/j.cgh.2025.02.018"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2021). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update. J. Hepatol., 75, 659\u2013689.","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.32739","article-title":"Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population","volume":"77","author":"Udompap","year":"2023","journal-title":"Hepatology"},{"key":"ref_11","first-page":"528","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr. Pract. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol."},{"key":"ref_12","unstructured":"American Diabetes Association Professional Practice Committee 4 (2025). Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025. Diabetes Care, 48, S59\u2013S85."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Guo, Z., Wu, D., Mao, R., Yao, Z., Wu, Q., and Lv, W. (2025). Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-91312-5"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e0629","DOI":"10.1097\/HC9.0000000000000629","article-title":"Increased MASH-associated liver cancer in younger demographics","volume":"9","author":"Danpanichkul","year":"2025","journal-title":"Hepatol. Commun."},{"key":"ref_16","first-page":"1999","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients with Type 2 Diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/MEG.0000000000002719","article-title":"Metabolic dysfunction-associated steatotic liver disease and the risk of mortality in individuals with type 2 diabetes: A systematic review and meta-analysis","volume":"36","author":"Wongtrakul","year":"2024","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Younossi, Z.M., Paik, J.M., Lazarus, J.V., Burra, P., Eguchi, Y., Tacke, F., Crespo, J., Villela-Nogueira, C.A., Brennan, P.N., and Al-Omar, H.A. (Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc., 2025). Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data from Nine Countries, Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc., advance online publication.","DOI":"10.1016\/j.cgh.2025.09.002"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4103\/sjg.SJG_122_18","article-title":"Nonalcoholic fatty liver disease burden\u2013Saudi Arabia and United Arab Emirates, 2017\u20132030","volume":"24","author":"Alswat","year":"2018","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: Heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_22","first-page":"e86963","article-title":"Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"17","author":"Hashim","year":"2025","journal-title":"Cureus"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"119053","DOI":"10.1016\/j.atherosclerosis.2024.119053","article-title":"Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"400","author":"Maccali","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPAR\u03b3 signaling and metabolism: The good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jhep.2023.07.004","article-title":"Treating NASH by targeting peroxisome proliferator-activated receptors","volume":"79","author":"Staels","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/VHRM.S993","article-title":"Peroxisome proliferator-activated receptor-gamma agonists and diabetes: Current evidence and future perspectives","volume":"4","author":"Chiarelli","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ju, Z., Su, M., Hong, J., Kim, E., and Jung, J.H. (2020). Anti-inflammatory effects of an optimized PPAR-\u03b3 agonist via NF-\u03baB pathway inhibition. Bioorganic Chem., 96.","DOI":"10.1016\/j.bioorg.2020.103611"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.2147\/DDDT.S524893","article-title":"Therapeutic Targeting of PPAR\u03b3 in Nonalcoholic Fatty Liver Disease: Efficacy, Safety, and Drug Development","volume":"19","author":"Zhou","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Stasi, C. (2021). Gut-liver the role of serotonin and its pathways in hepatic fibrogenesis. The Complex Interplay Between Gut-Brain, Gut-Liver, and Liver-Brain Axes, Academic Press. [1st ed.].","DOI":"10.1016\/B978-0-12-821927-0.00005-X"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2004.01.038","article-title":"Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet","volume":"315","author":"Kawaguchi","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_31","first-page":"411","article-title":"Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study","volume":"20","author":"Deng","year":"2017","journal-title":"Cancer Biomark. Sect. A Dis. Markers"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"35715","DOI":"10.1074\/jbc.M006577200","article-title":"Peroxisome proliferator-activated receptors and hepatic stellate cell activation","volume":"275","author":"Miyahara","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/hep4.1680","article-title":"Relationship of ELF and PIIINP with Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial","volume":"5","author":"Gawrieh","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102543","DOI":"10.1016\/j.clinre.2025.102543","article-title":"Efficacy and safety of dapagliflozin compared to pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: A randomized clinical trial","volume":"49","author":"Adel","year":"2025","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Sayadishahraki, M., Mirfendereski, S., Kachuei, A., Rafiee Zadeh, A., and Mirghaderi, A. (2023). Effect of Pioglitazone on Nonalcoholic Fatty Liver Disease in Morbid Obese Patients; a Randomized Controlled Trial. Adv. Biomed. Res., 12.","DOI":"10.4103\/abr.abr_354_21"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Lee, M., Hong, S., Cho, Y., Rhee, H., Yu, M.H., Bae, J., Lee, Y.H., Lee, B.W., Kang, E.S., and Cha, B.S. (2025). Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: A 24-week, open-label, randomized controlled trial. BMC Med., 23.","DOI":"10.1186\/s12916-025-04017-x"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e40356","DOI":"10.1097\/MD.0000000000040356","article-title":"The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial","volume":"103","author":"Khaliq","year":"2024","journal-title":"Medicine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s11845-025-03945-0","article-title":"Combination therapy with vitamin E and ertugliflozin in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: A randomized clinical trial","volume":"194","author":"Khaliq","year":"2025","journal-title":"Ir. J. Med. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e004981","DOI":"10.1136\/bmjdrc-2025-004981","article-title":"Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: Results from the EDICT study","volume":"13","author":"Puckett","year":"2025","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"108777","DOI":"10.1016\/j.jdiacomp.2024.108777","article-title":"FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD)","volume":"38","author":"Albert","year":"2024","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"104799","DOI":"10.1016\/j.phrs.2020.104799","article-title":"The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and\/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials","volume":"159","author":"Jalali","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/jdi.14246","article-title":"Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD","volume":"15","author":"Ito","year":"2024","journal-title":"J. Diabetes Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102279","DOI":"10.1016\/j.clinre.2023.102279","article-title":"Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"48","author":"Shargh","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"100737","DOI":"10.1016\/j.clinsp.2025.100737","article-title":"Long-term pioglitazone use in MASLD patients: Insights from a multicentric preliminary study","volume":"80","author":"Pereira","year":"2025","journal-title":"Clinics"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"102536","DOI":"10.1016\/j.jceh.2025.102536","article-title":"Factors Associated with Advanced Liver Fibrosis in a Population with Type 2 Diabetes: A Multicentric Study in Mexico City","volume":"15","year":"2025","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_47","unstructured":"Shi, Y., Kim, S.U., Yip, T.C., Tsochatzis, E., Petta, S., Nakajima, A., Hagstr\u00f6m, H., Bugianesi, E., Chan, W.K., and Boursier, J. (Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc., 2025). Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals with T2D and MASLD, Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc., advance online publication."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/dom.16049","article-title":"Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes-A real-world study","volume":"27","author":"Lee","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_49","unstructured":"(2025, April 04). ClinicalTrials.gov ID NCT04501406 Low-Dose Pioglitazone in Patients with NASH (AIM 2). Last Update Posted 4 April 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04501406?cond=NASH%20-%20Nonalcoholic%20Steatohepatitis&intr=pioglitazone&rank=2."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Markowska, J., Kasprzak-Drozd, K., Nizi\u0144ski, P., Dragan, M., Kondracka, A., Gondek, E., Oniszczuk, T., and Oniszczuk, A. (2024). Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Molecules, 29.","DOI":"10.3390\/molecules29225245"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2017.02.022","article-title":"Quercetin and pioglitazone synergistically reverse endothelial dysfunction in isolated aorta from fructose-streptozotocin (F-STZ)-induced diabetic rats","volume":"799","author":"Kunasegaran","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"108998","DOI":"10.1016\/j.jdiacomp.2025.108998","article-title":"Comparison of efficacy and safety of pioglitazone and SGLT2 inhibitors in treating Asian patients in MASLD associated with type 2 diabetes: A meta-analysis","volume":"39","author":"Liu","year":"2025","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e013927","DOI":"10.1136\/bmjopen-2016-013927","article-title":"Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: A systematic review and meta-analysis","volume":"7","author":"Liao","year":"2017","journal-title":"BMJ Open"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/cam4.1354","article-title":"Pioglitazone and bladder cancer risk: A systematic review and meta-analysis","volume":"7","author":"Tang","year":"2018","journal-title":"Cancer Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13561-023-00466-3","article-title":"Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: A Bayesian network model","volume":"13","author":"Nogueira","year":"2023","journal-title":"Health Econ. Rev."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/11\/1682\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:58:57Z","timestamp":1761760737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/11\/1682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":55,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["life15111682"],"URL":"https:\/\/doi.org\/10.3390\/life15111682","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}